Safety and Immunogenicity of a Vaccine for Cutaneous Leishmaniasis Using Recombinant Human Interleukin-12 and Aluminum Hydroxide Gel as Adjuvants

NCT00001906 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

50

Enrollment

NIH

Sponsor class

Conditions

Cutaneous Leishmaniasis

Interventions

BIOLOGICAL: Combination of autoclaved leishmania antigen with recombinant human interleukin-12 (rhIL-12) and aluminum hydroxide gel as adjuvants

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)